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This study reports a case of promyelocytic sarcoma that developed as a solitary sternal 
mass without any clinical evidence of acute promyelocytic leukemia. The case presented 
the diagnostic difficulties common to all aleukemic granulocytic sarcomas, and diagnosis 
was made possible by local identification of the PML/RARα fusion gene by fluorescent 
in situ hybridization. The patient was treated by surgery followed by chemotherapy plus 
all-trans retinoic acid therapy and local radiotherapy.
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INTRODUCTION
  Myeloid sarcoma (MS) (initially known as granulocytic 
sarcoma, and then chloroma) is a rare localized tumor com-
posed of immature granulocytic precursor cells. This extra-
medullary tumor can affect any organ and can present before, 
in concurrence with, or after the diagnosis of acute myeloid 
leukemia (AML) or other myeloproliferative disorders, or 
as a manifestation of disease relapse [1]. The World Health 
Organization (WHO) classification recognizes different var-
iants of this tumor based on the predominant cell type and 
the degree of cell maturation [2]. Extramedullary disease 
is associated with every cytological subset of French- 
American-British (FAB) individuals; the disease is frequently 
found in patients with a monocytic component (FAB M4 
and M5), but it is seldom found in patients with acute pro-
myelocytic leukemia (APL) [3].
  APL accounts for approximately 10% of AML cases, and 
is characterized by a favorable clinical outcome [4]. Several 
types of extramedullary leukemic infiltrates have been re-
ported in APL patients; the skin (leukemia cutis) and the 
central nervous system (CNS) are the preferred sites of extra-
medullary involvement in APL. Among primary extra-
medullary localizations, chloroma is an uncommon patho-
gnomonic lesion, and it is more appropriately termed as 
promyelocytic sarcoma (PS) when it occurs in this subset 
of leukemia.
  In this report, we present a case of PS that presented 
as a solitary sternal mass without any clinical evidence of 
hemopathy. A conclusive diagnosis of PS was made only 
after local identification of the PML/RARα fusion gene by 
using fluorescent in situ hybridization (FISH). 
CASE REPORT
  A 19-year-old man who had a history of asthma and re-
sultant steroid treatment presented with sternal pain, fever, 
and fatigue in December 2009. Physical examination revealed 
a solid sternal extramedullary mass with local erythema, 
and the patient reported persistent pain. Neither trauma 
nor infection was reported. Magnetic resonance imaging 
(MRI) scans showed edema, periosteal reaction, and irregular 
signals from the bone marrow (Fig. 1). Antibiotic therapy 
was initiated because of the putative diagnosis of osteomyelitis. 
However, the pain persisted, thereby prompting reevaluation. 
The blood cell count was normal: hemoglobin, 15.9 g/dL; 
red blood cells, 5.5×10
12/L; white blood cells, 7.4×10
9/L (with 
neutrophils, 3.2×10
9/L; eosinophils, 0.4×10
9/L; lymphocytes, Korean J Hematol 2011;46:52-6.
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Fig. 1. Magnetic resonance imaging of the sternum. Sagittal-weighted images (A to H) show injury to almost the entire sternum. The sternum shows
an obvious abnormality at the distal end with a centro-osseous necrotic mass measuring 24 mm in transverse section, 7 mm in thickness, and 20 
mm in height. The soft tissue swelling in the pre- and retro-sternal areas is significant with intense enhancement spanning nearly 50 mm.
2.9×10
9/L; and monocytes, 0.4×10
9/L); and platelets, 202× 
10
9/L. In March 2010, the patient underwent surgery. A 
lobulated tumor that was stuck to the sternum but did not 
infiltrate it was removed during surgery. Complementary 
biopsies of the sternum and the peri-sternal tissue were 
performed. Histopathological examination of the tissue re-
vealed an infiltration by myeloid cells, of which some cells 
had a promyelocytic morphology and contained azurophilic 
granulations and Auer rods. The immunophenotypic study 
was limited to specific antigens, but most of the cells did 
not express CD34. Cytogenetic studies of the PML/RARα 
fusion gene by using FISH (LSI probe) and PML/RARα dual 
color probe (Dual fusion translocation probe, Vysis/Abbot) 
showed t(15;17) (q22;q21-22) (Fig. 2). Diagnostic workup Korean J Hematol 2011;46:52-6.
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Fig. 2. The reciprocal and balanced t(15;21), involving the
PML gene on chromosome 15q22 and the RARα gene on 
chromosome 17q12.1, is a characteristic molecular 
feature of APL. In APL cells containing t(15;17), 1 orange 
(PML), 1 green (RARα), and 1 fusion (PML/RARα) signal 
pattern is observed (A). Two gene fusion products result 
from this translocation and encode the functional 
chimeric proteins: PML/RARα  and  RARα/PML. The LSI 
PML/RARα probe is a mixture of 2 FISH DNA probes. LSI
PML is labeled in spectrum orange and LSI RARα is labeled
in spectrum green (B).
of the patients, including determination of the coagulation 
profile and assessment of the bone marrow aspirate, yielded 
normal results, and neither atypical promyelocytes nor blast 
cells was detected in the peripheral blood and bone marrow. 
In addition, negative results were obtained in cytogenetic 
and PCR analysis for PML/RARα transcription in peripheral 
blood and bone marrow cells. Taken together, the results 
suggested a diagnosis of PS. The patient was treated in accord-
ance with the French APL-2006 trial: a combination of 
all-trans retinoic acid (ATRA) (45 mg/m
2/day for 30 days), 
idarubicin (12 mg/m
2/day for 3 days), and cytarabine (200 
mg/m
2/day for 7 days) was administered. Further evaluation 
of the patient after induction therapy was not possible be-
cause of the specific morphological and molecular results 
at the time of diagnosis. However, the patient still received 
2 additional courses of consolidation chemotherapy followed 
by local radiotherapy in the sternal region, and a 2-year 
maintenance therapy involving oral administration of 6-mer-
captopurine and methotrexate was scheduled.
DISCUSSION
  The problems related to the diagnosis and prognosis of 
MS can be attributed to its clinical mode of appearance. 
Since most patients never develop systemic disease, a correct 
and timely diagnosis may be rather difficult. Diagnosis is 
easier when MS is concomitant with leukemia [5-7], or when 
MS develops in patients previously treated for leukemia [8]. 
Diagnosis is more problematic when MS precedes acute 
leukemia. Cases of MS are often misdiagnosed as other neo-
plasms, mainly as malignant lymphomas. In the cases of 
APL, extramedullary disease is generally observed at the 
time of relapse and presents as a solitary localization or 
in association with the hematological features of the disease. 
The occurrence of extramedullary disease in patients with 
APL has been increasing since the introduction of all-trans 
retinoic acid (ATRA) therapy [8]. Such findings have raised 
several questions regarding the use of this therapy; the in-
crease in the occurrence of extramedullary diseases has been 
linked to a direct effect of ATRA on adhesion molecules, Korean J Hematol 2011;46:52-6.
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Table 1. Published cases of isolated myeloid sarcoma in APL at diagnosis.
Reference Site of involvement Diagnosis of APL Initial treatment
Kubonishi et al. (1984) [11] Mediastinal tumor APL diagnosed 8 mo later Surgery+radiotherapy
Ajarim et al. (1990) [6] Thymus Concomitant hematological features Chemotherapy
Brown et al. (1992) [7] Optic nerve Concomitant hematological features ATRA alone
Tosi et al. (1995) [12] L4-epidural Concomitant hematological features Surgery+ATRA+chemotherapy+
 radiotherapy
Savranlar et al. (2004) [10] Thoracic-epidural APL diagnosed 10 mo later Surgery+radiotherapy
Gopal et al. (2005) [14] Testicle Cytogenetic features at relapse Surgery
Fukushima et al. (2006) [5] Cerebellum Concomitant hematological features Surgery+chemotherapy
Worch et al. (2008) [13] Lytic lesions of humerus,
 tibia, femur
Molecular hematological features ATRA+chemotherapy
Present case (2010) Sternum Molecular features on tumor cells Surgery+ATRA+chemotherapy+
 radiotherapy
Abbreviations: APL, acute promyelocytic leukemia; ATRA, all-trans retinoic acid therapy; mo, months.
which increases the infiltration capability of blastic cells 
[9]. The increase in the occurrence of extramedullary disease 
can also be a consequence of the prolonged survival of pa-
tients who receive ATRA [8]. Furthermore, the occurrence 
of the ATRA syndrome has been recognized to be a significant 
risk factor for extramedullary involvement at relapse [9].
  The presence of an isolated localization is much more 
uncommon in APL at the time of initial diagnosis. In rare 
cases, MS originates in the subperiosteal regions of the bones 
(ribs, sternum, or orbital bones) several months before the 
clinical detection of leukemia, and subsequently spreads to 
soft tissues. MS can also originate in other regions, such 
as the spinal epidural space, thereby showing signs and symp-
toms of spinal compression. PS may have totally gone un-
detected on initial diagnosis [10-12], and it may actually 
be diagnosed later with bone marrow infiltration by promye-
locytic malignant cells at the time of relapse. PS may be 
correctly diagnosed initially by identifying the specific trans-
location and/or molecular rearrangement in the tumor cells 
and also by assessing the molecular hematological features, 
even though the bone marrow aspirate does not show any 
blastic infiltration [13, 14] (Table 1).
  A diagnosis of MS is considered as a possible sign of APL. 
In this report, we report a rare case of MS; diagnosis of 
the disease was made after surgical intervention and cytoge-
netic analysis of the tumor cells. Correct and timely diagnosis 
is a prerequisite for optimal treatment and outcome. There-
fore, establishing an accurate histological diagnosis is a funda-
mental requirement. The optimal management of patients 
with this form of APL has not been critically assessed. In 
some MS cases, the patients do not show any clear leukemic 
transformation in the later stages. However, the consensus 
is that all patients showing MS should be treated with in-
tensive chemotherapy [15]. When left untreated, most cases 
progress to overt leukemia; a majority of the cases show 
AML transformation in about 10 months [10-12, 14]. Similarly, 
therapy restricted to local procedures increases the risk of 
systemic disease. Radiation and intensive systemic therapy 
may therefore certainly be considered [15], and treatment 
might involve the same chemotherapeutic schedules that 
are generally used in leukemia with a “classic” presentation. 
The standard treatment for APL consists of ATRA combined 
with conventional chemotherapy [4]. Our patient could not 
be included into the French APL-2006 clinical trial, but 
he was treated similarly with an induction course combining 
ATRA with chemotherapy followed by 2 courses of con-
solidation chemotherapy and a 2-year maintenance therapy. 
Furthermore, complementary sternal irradiation was sched-
uled between the consolidation and maintenance phases.
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